Management of hepatitis B virus infection in liver transplant recipients: Prospects and challenges

Clinical Transplantation

Volumn 14, Issue SUPPL. 2, 2000, Pages 39-43

  Terrault, N ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibody; Famciclovir; HBlg; HBsAg; Hepatitis B virus; Lamivudine; Liver; Mutation; Transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; ANTISERUM; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MONOCLONAL ANTIBODY; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; GRAFT INFECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; PRIORITY JOURNAL; RECIPIENT; REINFECTION; TREATMENT FAILURE; VIRUS MUTATION; VIRUS REPLICATION;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LIVER TRANSPLANTATION; MUTATION; SURVIVAL RATE; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 0033864312     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin
2. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization
3. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation
4. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients
5. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization
6. Recurrent HBV/HDV infections under different immunoprophylaxis protocols
7. Absence of initial viral replication and long-term high dose immunoglobulin administration improve results of hepatitis B virus recurrence prophylaxis after liver transplantation
8. Long term lamivudine therapy of patients with recurrent hepatitis B post liver transplantation
9. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
10. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post orthotopic liver transplantation (OLT)
11. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
12. Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study
13. Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation
14. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin
15. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis
16. Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation
17. Hepatitis viruses
18. A topological model for hepatitis B surface antigen
19. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis
20. Vaccine-induced escape mutant of hepatitis B virus
21. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients
22. A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis
23. Mercury poisoning associated with hepatitis-B immunoglobulin (letter)
24. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin
25. Combined short-term hepatitis B immunoglobulin (HBIg) and long-term lamivudine versus HBIg monotherapy as hepatitis B virus prophylaxis in liver transplant recipients